Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
University of Nottingham · Royal Derby Hospital · +12 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
601
total citations
- FWCI
- 51.41
- Percentile
- 100%
- References
- 24
Citations per year
Authors
18- JRJ.F.R. RobertsonCorresponding
University of Nottingham, Royal Derby Hospital
- IMIgor M Bondarenko
Dnipro State Medical University
- ETEkaterina Trishkina
Leningrad Regional Cancer Center
- MDMikhail Dvorkin
Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"
- LPLawrence Panasci
Jewish General Hospital
Topics & keywords
Topics
Keywords
- Anastrozole
- Fulvestrant
- Medicine
- Internal medicine
- Hazard ratio
- Breast cancer
- Oncology
- Clinical endpoint
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.